Hardy Tadahisa S Kagimoto | President And Chief Executive Officer
Healios K. K.

Hardy Tadahisa S Kagimoto, President And Chief Executive Officer, Healios K. K.

Hardy TS Kagimoto, MD is founder, Chairman and CEO of HEALIOS K.K., a Tokyo-based, clinical-stage world leader in regenerative medicine and cell therapy.
After founding Healios in 2011, Dr. Kagimoto led the company’s listing on the Tokyo Stock Exchange in 2015 and has built the company to its current scale of more than 140 people across its Japan and US offices. Healios leverages the favorable Japanese regulatory framework for regenerative medicine to efficiently deliver results for patients and its stakeholders. It is currently running two pivotal clinical trials for ischemic stroke and acute respiratory distress syndrome using bone marrow-derived allogeneic somatic stem cells. At the same time, Healios is developing best-in-class, next generation pipeline assets in immuno-oncology, ophthalmology, and organ buds utilizing its innovative, proprietary universal donor iPS cell platform.
Dr. Kagimoto is a Kyushu University hospital trained medical doctor. Prior to founding Healios, he built and ran his first biotech company, Aqumen, and launched BBG250 which gained global de-facto-standard status as a surgical adjuvant in the ophthalmology community. Dr. Kagimoto lives in Tokyo with his wife and four children.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 14:00

Panel: The next generation of cell therapies

  • Revisiting MSCs, what have we learned?
  • Repurposed tools and modified cells
  • Sourcing clinical grade iPSCs

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 14:30

Roundtable: neurological & ophthalmic applications for ATMPs

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 16:00

Healios's Hybrid business strategy

Day 2: Thursday 20th May 2021 - Gene Therapy @ 12:00

Keynote panel discussion: Where are we with COVID now?

·There are 70+ CT clinical trials registered for COVID and ARDS related to COVID·Round up of COVID & ARDs related CT clinical trials·What are the short term and long-term effects of COVID on the industry going forward?·Head to head comparison of data from key players·Regulatory standpoint on cell therapies for COVID ARDs
last published: 10/May/21 08:45 GMT

back to speakers